{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T18:00:57Z","timestamp":1765994457950},"reference-count":63,"publisher":"Informa UK Limited","issue":"2","funder":[{"name":"National Research, Development and Innovation Office","award":["119809","125377","EFOP-3.6.2\u201316\u20132017\u201300006"],"award-info":[{"award-number":["119809","125377","EFOP-3.6.2\u201316\u20132017\u201300006"]}]},{"name":"New National Excellence Program of the Ministry of Human Capacities"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.2217\/imt-2017-0107","type":"journal-article","created":{"date-parts":[[2017,11,10]],"date-time":"2017-11-10T10:28:52Z","timestamp":1510309732000},"page":"107-117","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["A Review on Biosimilar Infliximab, CT-P13, in the Treatment of Inflammatory Bowel Disease"],"prefix":"10.1080","volume":"10","author":[{"given":"Klaudia","family":"Farkas","sequence":"first","affiliation":[{"name":"1st Department of Medicine, University of Szeged, Szeged, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"Moln\u00e1r","sequence":"additional","affiliation":[{"name":"1st Department of Medicine, University of Szeged, Szeged, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2017,11,10]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.10.001"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000358135"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2015.135"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv190"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"e_1_3_3_9_1","unstructured":"European Medicine Agency . Procedural advice for users of the centralised procedure for similar biological medicinal products applications . EMA\/940451\/2011 . www.ema.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_procedural_guideline\/2012\/04\/WC500125166.pdf ."},{"key":"e_1_3_3_10_1","unstructured":"World Health Organization Expert Committee on Biological Standardization . Guidelines on evaluation of similar biotherapeutic products ( 2009 ). www.who.int\/biologicals\/areas\/biological_therapeutics\/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf ."},{"key":"e_1_3_3_11_1","unstructured":"US Food and Drugs Administration . Demonstration of comparability of human biological products including therapeutic biotechnology-derived products ( 1996 ). www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm122879.htm ."},{"key":"e_1_3_3_12_1","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Comparability of biotechnological\/biological products subject to changes in their manufacturing process. Q5E ( 2004 ). www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Quality\/Q5E\/Step4\/Q5E_Guideline.pdf ."},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i2.197"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2014.05.005"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203090"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208786"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-0981-6"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208783"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203091"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-0930-4"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.2015.1067142"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0233-1"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-425744"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.5639\/gabij.2012.0101.005"},{"key":"e_1_3_3_25_1","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) . Assessment report: Remsima (infliximab) ( 2013 ). www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002576\/WC500151486.pdf ."},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.32221"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2015.1090310"},{"key":"e_1_3_3_28_1","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) . Assessment report: Inflectra. ( 2013 ). www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_Public_assessment_report\/human\/002778\/WC500151490.pdf ."},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-583617"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2015.1090311"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12432"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx002.098"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(17)30571-1"},{"key":"e_1_3_3_34_1","unstructured":"Clinical Trials Database: NCT02452151 . https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02452151?term=infliximab+and+biosimilar&rank=1 ."},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-014-3392-z"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12997"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474124.2015.1091309"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1064893"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2016.1149883"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001643"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv220"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1159\/000449088"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-017-4511-4"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw085"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000995"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv233"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw087"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-017-4661-4"},{"issue":"3","key":"e_1_3_3_49_1","first-page":"297","article-title":"Switching from Remicade\u00ae to Remsima\u00ae is well tolerated and feasible: a prospective, open-label study","volume":"11","author":"Buer LC","year":"2017","unstructured":"Buer LC , MoumBA , CvancarovaM , WarrenDJ , MedhusAW , H\u2298ivikML . Switching from Remicade\u00ae to Remsima\u00ae is well tolerated and feasible: a prospective, open-label study . J. Crohns Colitis11 ( 3 ), 297 \u2013 304 ( 2017 ).","journal-title":"J. Crohns Colitis"},{"issue":"6","key":"e_1_3_3_50_1","first-page":"690","article-title":"Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme","volume":"11","author":"Razanskaite V","year":"2017","unstructured":"Razanskaite V , BetteyM , DowneyLet al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme . J. Crohns Colitis11 ( 6 ), 690 \u2013 696 ( 2017 ).","journal-title":"J. Crohns Colitis"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30068-5"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1159\/000453343"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2017.1363885"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.03.011"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.06.007"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw138"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw090"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw198"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309290"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1323330"},{"key":"e_1_3_3_61_1","unstructured":"Celltrion Healthcare . The primary outcome from a RCT in Crohn\u2019s disease shows biosimilar infliximab is comparable to reference infliximab in terms of efficacy and safety ( 2017 ). www.celltrionhealthcare.com\/en\/news\/board\/detail.do?seq=46&division=R ."},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207764"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0240-7"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.155"},{"key":"e_1_3_3_65_1","doi-asserted-by":"crossref","unstructured":"Han S KimS KimJet al. The pharmacoeconomic impact of biosimilar infliximab (CT-P13) in Europe from January 2015 to June 2016 . Congress of the European Crohn\u2019s and Colitis Organisation (ECCO) ( 2017 ). P582 . www.ecco-ibd.eu\/publications\/congress-abstract-s\/abstracts-2017\/item\/p582-the-pharmacoeconomic-impact-of-biosimilar-infliximab-ct-p13-in-europe-from-january-2015-to-june-2016\u20132.html .","DOI":"10.1093\/ecco-jcc\/jjx002.706"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2017-0107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T15:13:01Z","timestamp":1715958781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2017-0107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,10]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.2217\/imt-2017-0107"],"URL":"https:\/\/doi.org\/10.2217\/imt-2017-0107","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-08-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}